Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDepei WuRZRobert ZeiserIYIbrahim Yakoub‐Agha

Discussion

Loading...

Member takes

Overview

Registry analysis shows NRAS/KRAS mutations affect leukemia-free survival in AML patients post-transplant, suggesting risk stratification implications.

Key Points

  • This research aims to evaluate the impact of NRAS and KRAS mutations on post-transplant outcomes in acute myeloid leukemia (AML) patients.
  • Retrospective registry analysis of AML patients who underwent allo-HCT from 2016-2021 with known NRAS/KRAS status.
  • Analysis involved overall survival, leukemia-free survival, cumulative incidence of relapse, and non-relapse mortality.
  • Included patients in various disease statuses at the time of transplant.
  • 2-year overall survival was 65% and leukemia-free survival was 54% for the entire cohort.
  • Patients with favorable cytogenetics had better outcomes, with 2-year leukemia-free survival of 77% in CR1 patients.
  • Cytomegalovirus positivity was associated with improved leukemia-free survival.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbeehttps://doi.org/10.1182/blood-2025-6395
View Full Paper
Ask AI
Bookmark
Share